LGT Group Foundation Purchases New Position in Illumina, Inc. (NASDAQ:ILMN)

LGT Group Foundation purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 17,358 shares of the life sciences company’s stock, valued at approximately $2,320,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new position in shares of Illumina during the 4th quarter worth approximately $152,000. Jones Financial Companies Lllp grew its position in shares of Illumina by 28.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,632 shares of the life sciences company’s stock worth $619,000 after purchasing an additional 1,030 shares in the last quarter. Metis Global Partners LLC grew its position in shares of Illumina by 6.4% during the 4th quarter. Metis Global Partners LLC now owns 3,803 shares of the life sciences company’s stock worth $508,000 after purchasing an additional 228 shares in the last quarter. QRG Capital Management Inc. grew its position in shares of Illumina by 35.1% during the 4th quarter. QRG Capital Management Inc. now owns 11,365 shares of the life sciences company’s stock worth $1,519,000 after purchasing an additional 2,954 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of Illumina during the 4th quarter worth approximately $10,875,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ILMN. Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Royal Bank of Canada decreased their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Guggenheim decreased their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, UBS Group upped their price target on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $155.45.

Illumina Price Performance

ILMN stock opened at $84.20 on Tuesday. The company has a fifty day moving average price of $122.36 and a 200-day moving average price of $132.81. The company has a market capitalization of $13.34 billion, a P/E ratio of -10.96, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 52-week low of $83.79 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.